The Enterprisers

  1. Medicines360 On A Mission For Women 5/1/2019

    Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.

  2. Lysogene: Mother of Invention 11/7/2018

    Karen Aiach had no background in healthcare when her young daughter received a diagnosis of a rare form of Sanfilippo syndrome. Aiach built her company, Lysogene, to create the world’s first treatment for the terrible disease.

  3. Apellis Advances On Autoimmunity 10/4/2018

    The unusual story of how Apellis was formed and what led it to target C3, the central factor in the innate-immunity complement system, to treat autoimmune diseases — starting with the ultra-rare blood condition, PNH.

  4. Reata Pharmaceuticals: Return & Reach Beyond 4/6/2018

    Reata refused to take what seemed like a dead-end trial as a losing proposition. Instead, the company went to work mining the trial for the very insights that subsequently saved it.

  5. CYDAN: Mission In The Orphan Space 3/7/2018

    Cydan is using a new business model in which they challenge the ways companies dealt with orphan drugs in the past.

  6. PolarityTE: Beyond Cells, To Whole Tissue 2/7/2018

    In this series on "Life Science Leadership In Action," we discuss PolarityTE, which focuses on regenerating lost tissues in their original complex forms.

  7. Prometic: New Tech Harvests Orphan Treatments 10/10/2017

    Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.

  8. Cytokinetics: Keeping Its Sights On Independence 9/8/2017

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  9. CohBar: Producing Mitochondria Medicine 2/1/2017

    Why shouldn’t our mitochondria want us to live long, prospering in good health? Why shouldn’t they — as symbiotic microbes turned cellular organelles with their own mini-genomes — carry genes that help ensure our healthful survival?

  10. Novavax: Scouting Past The Long Trail To Market 10/1/2016

    Clinical challenges lurk all along the pathway for any company developing new vaccine candidates and technology — and that goes at least twice for Novavax. As we go to press with this, the company is dealing with an anxious investment community about the “failed” Phase 3 trial of its RSV F vaccine in older adults, for protection against respiratory syncytial virus (RSV). (See “Press-Time Thunder.”)